MaxCyte®

Total Voting Rights and Block Listing Return

October 3, 2022

RNS Number : 5404B
MaxCyte, Inc.
03 October 2022

MaxCyte, Inc.

("MaxCyte" or the "Company")

TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN

Total Voting Rights

Date: 3 October 2022: MaxCyte (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, it has recently issued 47,429 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options. The new Common Stock will rank *pari passu* with the existing shares of common stock of the Company.

As of 30 September 2022, the total issued stock capital of the Company following the recent issue of the new Common Stock is 101,904,313 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

Block Listing Return

MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of *applicant*:		MaxCyte, Inc.		
Name of scheme:		MaxCyte Long Term Incentive Plan		
Period of return:	From:	1 March 2022	To:	30 September 2022
Balance of unallotted securities under scheme(s) from previous return:		12,177,084 ordinary shares of common stock at $0.01 each		

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	Nil
Less: Number of *securities* issued/allotted under scheme(s) during period (see LR3.5.7G):	647,481 ordinary shares of common stock at $0.01 each
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	11,529,603 ordinary shares of common stock at $0.01 each

Name of contact:	Ron Holtz, Chief Financial Officer
Telephone number of contact:	+1 301 944 1624

For further information, please contact:

MaxCyte Contacts:

US IR Adviser +1 415-937-5400
Gilmartin Group ir@maxcyte.com
David Deuchler, CFA

Nominated Adviser and Joint Corporate Broker
Panmure Gordon +44 (0)20 7886 2500
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

UK IR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation®platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual

property portfolio.

END

TVRUPGRWUUPPURW